

Appln No.: 10/075,947
Amendment Dated: April 25, 2004
Reply to Office Action of March 25, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (canceled)

11. (currently amended) T cells expressing a recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody, wherein the recombinant single chain peptide is encoded by a polynucleotide comprising a region encoding the variable region of the light chain of an anti-G_{D2} antibody linked to a region encoding the variable region of the heavy chain of an anti-G_{D2} antibody, wherein the variable region of the light chain is linked to the variable region of the heavy chain in an orientation whereby a peptide expressed from the polynucleotide binds to G_{D2}, and wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 2.

12-22. (canceled)

23. (currently amended) T cells according to claim 11, expressing a recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody, wherein the recombinant single chain peptide is encoded by a polynucleotide comprising a region encoding the variable region of the light chain of an anti-G_{D2} antibody linked to a region encoding the variable region of the heavy chain of an anti-G_{D2} antibody, wherein the variable region of the light chain is linked to the variable region of the heavy chain in an orientation whereby a peptide expressed from the polynucleotide binds to G_{D2}, and wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 1.

24-28. (cancelled)

29. (new) T cells according to claim 11, wherein the polynucleotide comprises, in contiguous sequence, the bases identified in SEQ. ID NO: 2.

31. (new) T cells according to claim 29, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.

32. (new) T cells according to claim 30, wherein the pre-therapeutic moiety is a pro-drug

Appln No.: 10/075,947
Amendment Dated: April 25, 2004
Reply to Office Action of March 25, 2004

converting enzyme.

33. (new) T cells according to claim 30, wherein the pre-therapeutic moiety is streptavidin.
34. (new) T cells according to claim 30, wherein the therapeutic moiety is a toxin.
35. (new) T cells according to claim 23, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.
36. (new) T cells according to claim 35, wherein the pre-therapeutic moiety is a pro-drug converting enzyme.
37. (new) T cells according to claim 35, wherein the pre-therapeutic moiety is streptavidin.
38. (new) T cells according to claim 35, wherein the therapeutic moiety is a toxin.
39. (new) T cells according to claim 11, wherein the polynucleotide further encodes a therapeutic or pre-therapeutic moiety.
40. (new) T cells according to claim 39, wherein the pre-therapeutic moiety is a pro-drug converting enzyme.
41. (new) T cells according to claim 40, wherein the pre-therapeutic moiety is streptavidin.
42. (new) T cells according to claim 40, wherein the therapeutic moiety is a toxin.